Analysts Offer Predictions for Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at William Blair issued their Q1 2026 EPS estimates for Krystal Biotech in a research note issued to investors on Wednesday, February 19th. William Blair analyst S. Corwin forecasts that the company will earn $1.91 per share for the quarter. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2026 earnings at $2.36 EPS, Q3 2026 earnings at $2.63 EPS and Q4 2026 earnings at $3.07 EPS.

A number of other equities research analysts also recently weighed in on the company. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Up 3.7 %

Shares of Krystal Biotech stock opened at $182.62 on Friday. The business has a 50-day moving average price of $157.37 and a 200 day moving average price of $175.23. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The firm has a market cap of $5.25 billion, a P/E ratio of 61.08 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.30 EPS.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank acquired a new stake in Krystal Biotech in the 4th quarter valued at approximately $34,391,000. Soleus Capital Management L.P. grew its stake in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after purchasing an additional 122,407 shares during the period. State Street Corp increased its holdings in shares of Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech during the fourth quarter valued at about $15,989,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).